Ionis Pharmaceuticals vs Telix Pharmaceuticals
Ionis Pharmaceuticals is the larger business, with $944m of revenue in fiscal 2025 against $804m for Telix Pharmaceuticals (1.2 times as much). Telix Pharmaceuticals grew faster (55.6% against 33.8%). Telix Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -0.9% against -40.4%. Telix Pharmaceuticals carries less debt relative to equity (97.5% against 370.6%).
| Latest fiscal year | Ionis PharmaceuticalsIONS, 2025 | Telix PharmaceuticalsTLX, 2025 |
|---|---|---|
| Revenue | $944m | $804m |
| Revenue growth | 33.8% | 55.6% |
| Net income | −$381m | −$7.1m |
| Operating margin | -40.4% | 3.7% |
| Net margin | -40.4% | -0.9% |
| Return on equity | -70.8% | -1.9% |
| Free cash flow | −$320m | −$43.0m |
| Cash | $372m | $142m |
| Total debt | $1.81bn | $405m |
| Debt to equity | 370.6% | 97.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 1,402 | — |
| Market value | $6.75bn | $3.05bn |
| Price vs our value range | — | — |
| Moat score | 35 (Weak) | — |
| Insider trades, 12 months | 2 buys, 116 sales | 3 buys, 0 sales |